Compare CNVS & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | IMA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | 218 | 15 |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 54.8M |
| IPO Year | 2016 | N/A |
| Metric | CNVS | IMA |
|---|---|---|
| Price | $2.64 | $5.85 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $16.00 |
| AVG Volume (30 Days) | 146.2K | ★ 370.3K |
| Earning Date | 02-17-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $84.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 59.13 | N/A |
| 52 Week Low | $1.77 | $3.94 |
| 52 Week High | $7.39 | $17.50 |
| Indicator | CNVS | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.57 | 52.28 |
| Support Level | $2.31 | $5.52 |
| Resistance Level | $3.47 | $7.17 |
| Average True Range (ATR) | 0.15 | 0.37 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 79.57 | 49.31 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.